“To ensure brand integrity we want open and direct communication with government and community stakeholders, specifically where we do business in the transportation, delivery and vending divisions. Gide LLC will work to the broadest acceptance and potential implementation for these in a variety of markets.” Linda Sampson, Marapharm CEO.
Gide LLC is an advisor, architect and executor of public affairs strategies. They combine traditional government relations with contemporary public interest and media campaigns. In addition to dealing with current situations Gide LLC works to pass laws that can make Marapharm more profitable and overturn laws that impede it. Gide LLC will activate meetings with city officials and managers to explain vending and delivery methods. Key stakeholders include casinos, supervisors, city council members, mayors and governing boards. Gide LLCs approach is to provide Marapharm with a strong voice to engage and enhance it’s business in strategic growth areas and states.
“We are looking forward to working with Gide LLC because they see our vision too, which is for Marapharm to continue to grow and perfect it’s businesses in the United States.” Linda Sampson, Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol “MDM” on the Canadian Securities Exchange, and in the United States, under the ticker symbol “MRPHF” on the OTCQB, and in Europe, under the ticker symbol “2M0” on the FSE.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.